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Highlights 
 There is a significant association between hs-TnT serum values and the
presence of ischemic heart disease as the cause of death
 Cardiopulmonary resuscitation does not increase the hs-TnT levels
 hs-TnT level increases in post-mortem, both in cases and controls
 More studies on cardiac biomarkers are needed in postmortem practice
1 
2 
ABSTRACT 3 
4 
INTRODUCTION: Ischemic heart disease (IHD) related to atherosclerotic coronary artery 5 
disease (CAD) is one of the most prevalent causes of death in Europe. Postmortem evaluation 6 
of IHD remains a challenge because of possible non-specific autopsy finding in some autopsy 7 
cases, especially in early myocardial ischemia. High-sensitive cardiac troponin T (hs-TnT) is 8 
used today in clinical practice as the “gold standard” to diagnose the myocardial ischemia, 9 
and might also be applied as an ancillary tool for post-mortem evaluation. 10 
11 
PURPOSE: The goal of this study is to evaluate the diagnostic value of post-mortem serum 12 
hs-TnT assay in cases of sudden death related to IHD. We will also investigate the influence 13 
of cardiopulmonary resuscitation (CPR) attempts on post-mortem hs-TnT levels. 14 
15 
METHODS: The hs-TnT values in serum were retrospectively analysed in 85 autopsy data. 16 
52 cases with clinical history and morphological results suggesting cardiac ischemia were 17 
included in the study group (mean age 53.5; age range 34-75) and 33 cases in the control 18 
group (mean age 40.4; age range 15-69). The group’s statistical comparison was performed 19 
using logistic regression model. 20 
21 
RESULTS: Our study showed a significant non-linear association between hs-TnT serum 22 
values and post-mortem diagnosis of sudden deaths related to IHD (p-value 0.005). The shape 23 
of the relationship is showing that the probability of death due to IHD increases quickly with 24 
a light level of hs-TnT (maximum around 90ng/L) then decreases slightly while remaining at 25 
*Manuscript (without author details)
2 
high in values. No significant difference in the hs-TnT serum values was found between the 26 
CPR and the non-CPR cases (p-value 0.304). 27 
28 
CONCLUSION: The measurement of hs-TnT serum values might be considered as an 29 
ancillary tool for the evaluation of death related to IHD, while taking necessary precautions in 30 
the interpretation of the results. 31 
32 
33 
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INTRODUCTION 35 
 36 
One of the most prevalent causes of death in Europe is ischemic heart disease (IHD) related to 37 
atherosclerotic coronary artery disease [1]. In clinical medicine, the diagnosis of IHD is based 38 
on clinical symptoms, electrocardiogram and biochemical markers. Post-mortem evaluation is 39 
more complicated as the anamnesis and diagnostic method are limited. Moreover, autopsy 40 
findings are not always specific for sudden death related to IHD, particularly if arrhythmias 41 
follow an acute coronary event or after a resuscitation attempt [2]. Forensic pathologists have 42 
turned towards the use of cardiac biomarkers initially developed in clinical medicine in an 43 
attempt to facilitate diagnosis of post-mortem IHD. These markers could become useful when 44 
morphological results are not conclusive at the autopsy.  45 
 46 
Among biomarkers, cardiac troponin (cTn) is the most frequently used in clinical practice as 47 
more sensitive and specific marker of cardiomyocyte injury than other biomarkers [3]. The 48 
troponin is a protein complex released in the blood flow after a myocardial injury. The 49 
clinical measurements of troponin appeared first in the mid-2000s and is considered by 50 
clinicians as the “gold standard” for acute myocardial infarction (AMI) diagnosis [4]. Last 51 
years, the old cTn measurement was replaced by the high-sensitive cardiac troponin T (hs-52 
TnT) assay, using the same immunoassay method with new antibodies, more sensitive, able to 53 
detect AMI at an earlier time-point than old cTn tests.  AMI can be reliably identified within 3 54 
h after admission with up to 100% sensitivity and up to 100% negative predictive value using  55 
hs-TnT assay, indicating that observation time may be reduced for the rule-out and rule-in of 56 
AMI, with various clinical algorithms [4-6]. Today, the hs-TnT assay is the “gold standard” 57 
for AMI diagnosis in clinical practice [4,5,7]. It is however important to notice that the 58 
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increase of the level of troponin reflects the myocardial cells’ necrosis and is thus not specific 59 
[5].  60 
 61 
Many clinical cardiac biomarkers were tested in post-mortem examination [8-22]. The post-62 
mortem experimental use of the old cTn assay started early already in the 2000s. The added 63 
value of its studies outcomes in forensic diagnosis always remained controversial, especially 64 
concerning the cause of death. There are also different opinions about the effects of 65 
cardiopulmonary resuscitation (CPR) on the increase of cTn level. Some authors suggested 66 
that the potential cardiac trauma could affect the release of troponin [23], however the 67 
scientific literature reports mainly that the effects on troponin level were non-significant in 68 
post-mortem [10,20,24]. To date, only one study has been driven using the new  hs-TnT assay 69 
on postmortem serum and pericardial fluid by González-Herrera et al. in 2016 [25] but did not 70 
focus on IHD. The authors showed that serum levels do not show any correlation with any 71 
cause of death and that low hs-TnT levels in pericardial fluid allowed the exclusion of the 72 
heart damage.  73 
 74 
Then, although many studies concerned the evaluation of biomarkers in postmortem, 75 
literature remains rather uncertain about the post-mortem diagnosis value of hs-TnT. Points of 76 
view emerged that troponin could be useful as an ancillary diagnostic tool to identify the 77 
cause of death, while one must remain cautious when interpreting the results. Therefore, this 78 
new biomarker requires more post-mortem studies. The goal of our study is therefore to 79 
evaluate the diagnostic value of post-mortem hs-TnT’s assays. We will focus on IHD’s 80 
sudden death cases related to atherosclerotic coronary artery disease, with or without 81 
morphological signs of cardiac ischemia. The influence of CPR attempts on post-mortem hs-82 
TnT levels will also be evaluated. 83 
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 84 
MATERIAL AND METHODS 85 
 86 
Cases  87 
The retrospective study was performed on autopsy data retrieved from the database of 88 
autopsies conducted by the University Center of Legal Medicine in Lausanne (CURML) 89 
between 2012 and 2015. The estimated post-mortem period did not exceed 72 hours. Study 90 
cases were selected on the basis of clinical history and/or morphological results suggesting 91 
the death from cardiac ischemia; this included cases with an acute coronary thrombosis or 92 
with signs of an acute myocardial ischemia, cases with coronary stenosis > 75 % with or 93 
without signs of an acute myocardial ischemia and without other cause of death found at 94 
autopsy and during toxicological analyses. Control cases included cases of violent death as 95 
hanging, strangulation, extra thoracic trauma, without an extended agony and without clinical 96 
or autopsy findings suggesting any cardiovascular disease.  97 
Considering that other causes than IHD, cardiac or not, can lead to an increase of hs-TnT as 98 
myocarditis, pericarditis, different kinds of heart failure, chronic renal failure, cerebrovascular 99 
accidents, acute pulmonary embolism, chronic obstructive pulmonary disease, drug 100 
intoxication and other acute non-cardiac critical illness [25,26,5], such cases were excluded 101 
from the study. Exclusion criteria included also advanced cadaveric deterioration and 102 
postoperative death. Person who had previously refused in a written document to give his/her 103 
corporal substance for research use were excluded. 104 
In each case, the examination of the heart involved macroscopical and histological 105 
evaluations. The histological examination was performed including at least five different 106 
topographic locations; namely left ventricle (anterior, lateral, posterior), interventricular 107 
septum and lateral wall of the right ventricle. The sections were routinely stained with 108 
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haematoxylin–eosin, followed in selected cases by immunochemistry (fibronectin and C5b-9). 109 
The body and heart weights were recorded for each case. 110 
This study received the ethical approval by the Cantonal Commission for the Ethics of Human 111 
Research (CER-VD). 112 
 113 
Biochemical analyses 114 
Peripheral blood from the femoral veins was systematically collected as soon as possible upon 115 
arrival of the bodies at the morgue and prior to autopsy. Blood was collected by aspiration 116 
with sterile needles and syringes from the femoral vein(s). Blood samples were drawn after 117 
clamping the vein(s) at the proximal end and lifting the lower limb(s) for several minutes. 118 
Samples were stored in preservative free gel serum separator tubes, that were centrifuged 119 
immediately post collection at 3000g for 15 min. After centrifugation, the separated 120 
supernatant (postmortem serum) was collected and stored in preservative free tubes. 121 
Postmortem serum samples were transferred to the laboratories immediately post collection. 122 
When analyses were delayed, samples were stored at - 20°C. 123 
Levels of postmortem serum cardiac troponin T were measured with hs-TnT reagents by 124 
electrochemiluminescence immunoassay (ECLIA). Results were expressed in nanograms per 125 
liter [19]. Cases with the troponin values higher than 10’000ng/L were excluded as considered 126 
as excessively altered and outside the analytical range. 127 
 128 
Statistical analyses 129 
Categorical data were summarized by their frequencies and percentages. For the age, the body 130 
weight and the hearth weight, the summary was given by their mean (sd) and range. 131 
Univariate logistic regression was performed to assess the association between each predictor 132 
and the outcome “cause of death” (reported as Odds-Ratios (OR) and p-values). The 133 
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functional form of the relationship between the continuous variables (hs-TnT levels, age, 134 
body weight and hearth weight) and the probability of death due to IHD was checked using a 135 
fractional polynomial model. The linearity assumption was confirmed except for the troponin 136 
T (hs-TnT) level (Figure 3). The level of the troponin T (hs-TnT) was then coded into three 137 
categories (≤12 coded by 0, [13-2250] coded by 1 and ≥ 2251 coded by 2) to assess the risk of 138 
death due to IHD when being in the categories 1 or 2 compared to the reference category 0. 139 
 140 
 141 
RESULTS 142 
 143 
A total of 85 cases (68 males and 17 females) were selected, 52 for the study group (age range 144 
34-75) and 33 for the control group (age range 15-69). Among those from the study group, 145 
acute thrombosis was found in 19 cases, 23 cases presented a severe atherosclerosis (with 146 
>75% of luminal stenosis) without coronary thrombosis and without other cause of death 147 
found at autopsy and during toxicological analyses and finally 10 cases had coronary luminal 148 
stenosis 50-75% and signs of an acute myocardial ischemia confirmed by immunochemistry 149 
and without other cause of death found at autopsy and during toxicological analyses. The 150 
control group included 23 cases of hangings or other asphyxia and 10 traumatic deaths. The 151 
manual CRP was performed in 28 cases from the study group and in 15 control cases. 152 
The troponin levels varied between 3 and 9687 ng/L. Complementary characteristics about 153 
cases and control are summarized in Table 1 and data related to coronary lesions in Table 2.   154 
 155 
 156 
 157 
 158 
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Statistical results 159 
 160 
No statistical correlation with hs-TnT values were found considering the time period between 161 
the death and the serum sample analysis measured for both cases and controls (Fig 1). There 162 
were also no significant differences between hs-TnT values of reanimated and non-163 
reanimated cases from the control group (p-value 0.304; Fig. 2). Therefore, samples of cases 164 
and controls were taken without taking those characteristics into account.  165 
 166 
A non-linear significant association between hs-TnT serum values and the presence of IHD 167 
(p-value 0.005. Fig.3) was observed. The shape of the relationship is showing that the 168 
probability of death due to IHD increases quickly with a light level of hs-TnT (maximum 169 
around 90ng/L), then decreases slightly while remaining at a high level.  170 
 171 
It was also noticed that the increase of hs-TnT levels in elderly patients with heavy heart 172 
weight, in presence of atherosclerosis or of cardiovascular symptoms before death (prodome), 173 
were significantly associated with a high probability of being included in the “study case” 174 
category.   175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
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DISCUSSION 184 
 185 
The use of clinical medicine biomarkers is a challenge for the forensic pathologists. While 186 
their interpretation is established in a clinical context, it is not far the case for post-mortem 187 
use. The actual challenge when using post-mortem biomarkers lies in the interpretation of 188 
these values that need to be adapted to the context of post mortem evaluation.  189 
 190 
The values of hs-TnT observed in this study and their interpretation are different from the 191 
ones seen in clinical medicine. The results of this study demonstrate that the hs-TnT level 192 
increases in post-mortem, both in cases and controls. This fact is often mentioned in the 193 
literature. Thus, regardless of the technique used (TnI, TnT, hs-TnT), levels of cardiac 194 
biomarkers are usually significantly higher than the reference range for living patients 195 
[27,28,25,21,22]. The reason for this upsurge is unclear; haemolysis and autolysis were 196 
suggested [28,29], as well as non-specific lesions and "invisible" infarction due to hypoxia of 197 
the myocardium during terminal agony [21,22]. It seems thus clear that the references values 198 
used clinically (ante-mortem) could be meaningless or questionable in the post-mortem 199 
context.  200 
 201 
This study revealed a non-linear significant association between hs-TnT serum values and the 202 
presence of IHD. This result differ from the findings of the González-Herrera et al. study, 203 
reporting no correlation between the different causes of death and the serum levels of cTnT 204 
[25].  An increase of probability of mortality from the IHD group with an increase of hs-TnT 205 
level was noticed, with a peak value around 90 ng/L. Above this value, the probability does 206 
not increase anymore, on the contrary to the use of hs-TnT in clinical medicine [4]. Moreover, 207 
beyond this limit, a slight decrease of the probability of IHD was observed. Therefore, 208 
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according to the results of our study, very high values of hs-TnT (as 2500 ng/L) were not 209 
correlated with a higher probability of IHD-related death. It was observed also that the 210 
correlation between the increase of hs-TnT and the probability of IHD death was higher in 211 
older victims, with an increased weight of heart, and atherosclerosis and cardiovascular 212 
symptoms before death (prodromes). Those results are not surprising and are in accordance 213 
with literature, clinical data as well as with physiopathology of the myocardial ischemia [30].  214 
 215 
This study showed that the attempt of a CPR does not seem to lead to a significant increase of 216 
post-mortem hs-TnT. These findings are in accordance with the results found in scientific 217 
literature [10,20,31] concerning the old troponine assay. Also, clinical studies about the hs-218 
TnT support that CPR may lead to a non-negligible increase of troponin in survivors [23]. No 219 
other evaluation was reported to this day for post-mortem evaluation of hs-TnT in reanimated 220 
cases. 221 
 222 
Post-mortem troponine levels often depend on sampling sites. It was reported that pericardial 223 
fluid would be the most representative sample site (more direct “salting out” of troponin from 224 
the myocardium to the sample site due to the proximity of each other) [28,21,22]. The 225 
troponin in pericardial fluid seems to show a better negative predictive value for post-mortem 226 
investigations than serum. This has been raised regarding the old troponin assay [14,16,17], as 227 
well as in the single post-mortem evaluation of hs-TnT assay [25]. The hs-TnT levels found in 228 
this study were measured only in serum samples and the evaluation of the hs-TnT levels in 229 
pericardial fluid for the post-mortem diagnosis of IHD would be interesting in future studies. 230 
 231 
Finally, it should also be underlined that, in a clinical context, it has recently been 232 
demonstrated that the specificity of hs-TnT for acute myocardial infarction is very low as the 233 
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increased values are observed in myocardial damage of any origin [26,32]. Therefore, the 234 
interpretation of a rise of the hs-TnT should be very careful and that more studies with larger 235 
samples could be useful. 236 
 237 
Study limitation 238 
 239 
The essential limitation of this study is related to the post-mortem context, impossible to be 240 
ruled out. This could lead to a biased increase of hs-TnT as reported for other post-mortem 241 
studies. The number of cases and controls included in this study is relatively small to obtain a 242 
good significance of the results. For practical reasons,  hs-TnT levels in pericardial fluid were 243 
not tested in this study. Therefore, we suggest performing more studies to further our 244 
knowledge in this interesting topic.  245 
 246 
 247 
 248 
CONCLUSION 249 
 250 
This study showed a non-linear significant association between hs-TnT serum values and the 251 
presence of IHD as the cause of death, with a different profile compared to the clinical field 252 
(peak around 90ng/L, then slight decrease of the probability). It was however impossible to 253 
determine a cut-off value as for living patients in clinical medicine, probably because of the 254 
non-specific and unpredictable rise of hs-TnT due to post-mortem alterations. No significant 255 
difference of hs-TnT serum values was found between the CPR and the non-CPR cases. 256 
 257 
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It seems reasonable to state that hs-TnT assay in serum can be considered as an additional 258 
tool for the evaluation of death related to IHD, while remaining cautious when interpreting 259 
the results. However, the use of this new high-sensitive assay requires more studies, 260 
especially with a focus on the pericardial fluid. 261 
 262 
 263 
 264 
 265 
 266 
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Legends 268 
269 
Fig. 1; Description of the variability of hs-TnT level in serum according to the post-mortem 270 
period in the two groups; cases and controls. 271 
272 
Fig. 2; Distribution of hs-TnT level in serum for control-cases reanimated versus not 273 
reanimated. No significant difference were noticed (two sample Wilcoxon test). 274 
275 
Fig. 3; Fig(a): fitted non-linear relation-ship between the hs-TnT level in serum and the 276 
predicted(logit)+residuals for  death related to IHD. Fig(b): The probability of death related to 277 
IHD according to the hs-TnT level in serum. Fig(c): the same as Fig (a) with the zoom for the 278 
hs-TnT level in serum between [3-2250]. Fig(d): the same as Fig(b) with the zoom for the hs-279 
TnT level in serum between [3-2250]. The two red vertical lines correspond to the hs-TnT 280 
level in serum=12 and 2250. Blue dashed horizontal line in Fig(d) indicate that the probability  281 
of  death related to IHD was upper to 50% for  the hs-TnT level in serum between [3-2250]. 282 
283 
Table 1; Summary of data relating the main characteristics including the number, the age, the 284 
body weight, the heart weight and the hs-TnT values for cases and controls. The association 285 
between each characteristic and the outcome measured using the OR and associated p-value. 286 
287 
Table 2; Summary of data in subgroups of cases and controls. For statistical analyses, the 288 
level of the troponin T (hs-TnT) was coded into three categories (≤12, [13-2250] and ≥ 2251) 289 
to assess the risk of death due to IHD (for details see Statistical analyses). 290 
291 
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Fig.1 Description of the variability of hs-TnT level  in serum (ng/L) according to the post-
mortem period (day) in the two groups; cases and controls. 
Figure 1
  
Fig. 2 Distribution of hs-TnT level in serum (ng/L) for control-cases reanimated versus not 
reanimated. No significant difference were noticed (two sample Wilcoxon test). 
 
Figure 2
  
Fig. 3 Fig(a): fitted non linear relation-ship between the hs-TnT level in serum (ng/L) and the 
predicted(logit)+residuals for  death related to IHD. Fig(b): The probability of  death 
related to IHD according to the hs-TnT level in serum (ng/L). Fig(c): the same as Fig(a) 
with the zoom for the hs-TnT level in serum (ng/L) between [3-2250]. Fig(d): the same 
as Fig(b) with the zoom for the hs-TnT level in serum (ng/L) between [3-2250]. The 
two red vertical lines correspond to the hs-TnT level in serum=12 and 2250 (ng/L). Blue 
dashed horizontal line in Fig(d) indicate that the probability  of  death related to IHD 
was upper to 50% for  the hs-TnT level in serum between [3-2250]. 
 
Figure 3
Variable Cases 
N (%) 
Controls 
N (%) 
Odd 
ratio 
p- value 
N (%) 52 (61.2) 33(38.8) 
Sex 
Male, n (%) 45 (86.5) 23 (69.7) 2.79 0.06 
Age [y] 
Mean (sd) 
min-max 
53.54 (9.5) 
34-75 
40.42 (14.1) 
15-69 
1.09 <0.0001 
Body weight [kg] 
Mean (sd) 
min-max 
82.12 (14.9) 
55-140 
75.36 (18) 
43-121 
1.03 0.07 
Heart weight [g] 
mean (sd) 
min-max 
477.50 (108.9) 
285-790 
350.76 (90.8) 
175-565 
1.01 <0.0001 
Hs-TnT[ng/L] 
≤12[ref] 
[13-2250] 
>2250 
4(7.7) 
46(88.5) 
2(3.8) 
10(30.3) 
19(57.6) 
2(3.8) 
- 
6.05 
1.25 
0.005 
0.83 
Table 1 Summary of data relating the main characteristics including the number, the age, the 
body weight, the heart weight and the hs-TnT values for cases and controls. The association 
between each characteristic and the outcome measured using the OR and associated p-value. 
Table 1
Table 2; Summary of data in subgroups of cases and controls. For statistical analyses, the level of the troponin T (hs-TnT) was coded into three 
categories (≤12, [13-2250] and ≥ 2251) to assess the risk of death due to IHD (for details see Statistical analyses). 
Coronary lesions Cases 
n 
Sex  
Male, 
n(%) 
Age 
(y) 
Mean (sd) 
min-max 
Heart weight 
(g) 
Mean (sd) min-
max 
Lungs weight 
(g) 
Mean (sd) min-max 
Hs TnT levels 
(ng/L) 
HsTn level 
Mean (sd) 
min-max 
 12 13-2250 >22
50 
Cases Acute coronary 
thrombosis 
19 15 (78.9) 47 (7.7) 
34-67 
446.3 (80.9) 
285-640 
1834.5 (607) 
600-2900 
1 16 2 1128.9 (2365.7) 
4-9687 
Coronary stenosis 
<75% with signs of 
myocardial ischemia 
10 9 (90) 58.3 (8.9) 
47-75 
551 (162.5) 
345-790 
1711 (440.1) 
1235-2350 
1 9 0 63.4 (90.3) 
12-317 
Coronary stenosis 
>75% 
23 21(91.3) 56.1 (9.2) 
37-70 
471.3 (89) 
315-650 
1605.2 (377.7) 
1050-2470 
2 21 0 211.8 (331.7) 
8-1191 
All  study cases 
52 45 (85.5) 53.5 (9.5) 
34-75 
477.5 (108.9) 
285-790 
1709.3 (486.3) 
600-2900 
4 46 2 518.3 (1498) 
4-4687 
Controls  None 33 23 (69.7) 40.4 (14.1) 
15-69 
350.8 (90.8) 
175-565 
1081.7 (329.4) 
495-1720 
10 19 2 935.5 (942.8) 
3-7786 
Table 2
